FOXM1 and ovarian serous carcinoma: Notably, the study also revealed that FOXM1 overexpression was an independent indicator of worse disease-specific survival in non-serous rather than in serous cases, suggesting that FOXM1 might have a more dominant role in dictating the clinical aggressiveness in non-serous ovarian carcinomas than in serous ones.